Leerink Partners on Agios Pharma (AGIO): NVO's Ph3 trial results likely to pressure shares
Tweet Send to a Friend
Leerink Partners analyst Andrew Berens reiterated an Outperform rating and $60.00 price target on Agios Pharma (NASDAQ: AGIO)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
